Conclusion
In summary, we present the experience of a moderate volume of VOM ethanol infusions in routine practice of AF ablation from a single medical center. Our demonstration of the feasibility of growing this program in a previously inexperienced center should allay trepidation to other operators or readers considering adopting this technique into their repertoire. While the high efficacy is laudable, the rate of delayed pericardial effusions should be noted and operators prepared for this complication with early echocardiographic follow-up and for informed consent discussions with patients. Further study of VOM ethanol infusion is needed to determine the marginal benefit and risks across centers.